Nilotinib
| Evidence Level: L4 | Predicted Indications: 1 |
Table of Contents
Nilotinib: From Chronic Myeloid Leukaemia to Dermatofibrosarcoma Protuberans
One-Sentence Summary
Nilotinib is a BCR-ABL tyrosine kinase inhibitor originally developed for chronic myeloid leukaemia (background pharmacology; not itself recorded in this evidence pack). The TxGNN model predicts potential efficacy in dermatofibrosarcoma protuberans (DFSP), but this is currently supported only by 0 clinical trials and 1 mechanistic review article — evidence is preclinical/class-level only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Chronic myeloid leukaemia (CML) — general pharmacological background; not present in this evidence pack (original_indications empty) |
| Predicted New Indication | Dermatofibrosarcoma protuberans |
| TxGNN Prediction Score | 99.31% |
| Evidence Level | L4 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack (data gap DG002). Based on the repurposing rationale supplied, nilotinib is a small-molecule inhibitor of PDGFR, KIT and BCR-ABL kinases — the same tyrosine kinases targeted by imatinib.
DFSP is driven by the COL1A1-PDGFB fusion gene, which causes constitutive activation of PDGFR-β. Imatinib, which shares nilotinib’s PDGFR-inhibitory activity, is already approved for DFSP. This creates a plausible class-level mechanistic rationale for nilotinib in the same disease.
However, the evidence pack is explicit that this link is inferential and class-based, not nilotinib-specific: no clinical trial or case-level data for nilotinib in DFSP currently exists, only a general review of PDGFR-inhibitor pharmacology. The prediction should therefore be treated as a research hypothesis rather than an evidence-backed indication.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 29408302 | 2018 | Review | Pharmacological Research | Reviews the role of small-molecule PDGFR inhibitors (a class including nilotinib) in neoplastic disorders; discusses PDGF/PDGFR signalling relevant to tumours such as DFSP, without nilotinib-specific clinical data |
UK Market Information
Nilotinib currently holds no UK marketing authorisations in this evidence pack, and no product-level licence information is available.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (BCR-ABL/PDGFR/KIT tyrosine kinase inhibitor) — based on general pharmacological class knowledge, as DrugBank category data was not returned in this pack |
| Myelosuppression Risk | Please refer to the SmPC warnings and precautions |
| Emetogenicity Classification | Please refer to the SmPC warnings and precautions |
| Monitoring Items | Please refer to the SmPC warnings and precautions |
| Handling Protection | Please refer to the SmPC warnings and precautions |
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: This evidence pack flags a Blocking data gap (DG001) — full label warnings and contraindications have not yet been retrieved. This prevents completion of the S1 initial safety assessment and must be resolved before any further evaluation proceeds.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence is limited to a class-level mechanistic inference (L4) with no nilotinib-specific clinical trials in DFSP, the drug holds no UK marketing authorisation, and a blocking safety data gap (missing warnings/contraindications) prevents initial safety evaluation.
To proceed, the following is needed:
- Resolution of blocking data gap DG001: full label warnings and contraindications
- Resolution of data gap DG002: confirmed mechanism of action / DrugBank category data
- Nilotinib-specific preclinical or clinical evidence in DFSP (current evidence is imatinib-by-analogy only)
- Confirmation of any UK/EU marketing authorisation pathway, since the drug is currently not marketed in the UK
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.